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Abstract
In this paper we have proposed a model for the distribution of allelic probabilities for
generating populations as reliably as possible. Our objective was to develop such a model
which would allow simulating allelic probabilities with different observed truncation and de-
gree of noise. In addition, we have also introduced here a complete new approach to analyze
a genome-wide association study (GWAS) dataset, starting from a new test of association
with a statistical distribution and two effect sizes of each genotype. The new methodologi-
cal approach was applied to a real data set together with a Monte Carlo experiment which
showed the power performance of our new method. Finally, we compared the new method
based on beta distribution with the conventional method (based on Chi-Squared distribu-
tion) using the agreement Kappa index and a principal component analysis (PCA). Both
the analyses show found differences existed between both the approaches while selecting the
single nucleotide polymorphisms (SNPs) in association.
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1 Introduction
A fundamental point in a genome-wide association study (GWAS) is to define a model for allelic
probabilities. A good model must strongly depend on the observed truncation and the degree of
noise that distort the observed (empirical) distribution from the expected one. By controlling
the truncation and the degree of noise, allelic probabilities can be simulated in a more reliable
scenario.
The Human Genome Project (Lander et al. [2001]) and the successive improvements on phys-
ical and genetic maps of the human genome have boosted the post-genome era (Altshuler et al.
[2010], Frazer et al. [2007], Sachidanandam et al. [2001]). Concomitant technological achieve-
ments in the genetic field have been successfully applied to uncover thousands of genetic variants
linked to multiple phenotypes. The deep characterization of loci involved in both Mendelian and
complex disorders will further help in improving diagnostic resolution and, ultimately, provide
clues on the design of next generation therapeutics based on etiology, rather than in symptoms
or clinical findings.
The genome-wide association studies (GWAS) appear to be unstoppable. The develop-
ment of high density genome-wide panels of single nucleotide polymorphism (SNPs) and its
application to bio-banked samples, accumulated during the last century, are the key elements
explaining GWAS emergence. Till, date ongoing GWAS projects have published 1350 GWAS
documents and more than 1800 GWAS significant loci (www.genome.gov/gwastudies; Freeze
Dec/2012) (Hindorff et al. [2009]). The new loci have been detected using relatively well stan-
dardized methods based on linear additive models with or without covariants, a case-control
design, by applying extensive quality control to raw genotyping data, by increasing density of
markers based on inference of many non-genotyped markers using high performance compu-
tation (HPC), imputation techniques and by increasingly improved reference panels of single
nucleotides polymorphisms (SNPs) (de Bakker et al. [2008]).
In spite of these successes, most GWAS findings, typically of small effect sizes, leave a large
fraction of disease susceptibility still unexplained; a phenomenon commonly known as “the
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case of the missing heritability” (Meesters et al. [2012]). Several potential explanations for this
phenomenon were proposed (Manolio et al. [2009]). An excessive simplification of statistical
methods applied to GWAS datasets might account for this problem. In this regard, allelic
and additive models pervasively applied to GWAS data could be the genuine spherical cow
(Shelton and Cliffe [2007]) on genetic research. Therefore, it is necessary to perform a continuous
re-analysis and re-cycling of GWAS data by applying novel statistical methods to uncover those
loci that match poorly with linear models (see Ruiz-Mar´ın et al. [2010]).
Here, we have proposed a model for the distribution of allelic probabilities which allows to
simulate allelic probabilities with different observed truncation and degree of noise. We have also
introduced a complete new approach to GWAS analysis, starting from a new test for association
and two effect sizes of each genotype. The new methodological approach was applied to a real
data set together with a Monte Carlo experiment which showed the power performance of our
new method and compared the new method with the conventional method.
2 Materials and Methods
2.1 Modeling Allelic Probability Distribution
Allele frequency refers to the proportion of a certain allele on a genetic locus of population.
These proportions often exhibit extra variation that cannot be explained by a simple binomial
distribution. The proportion (or binomial parameter p) does not remain constant in the course
of collecting data. Considering the situation, it would be useful to assume that the binomial
parameter p varies between observations. The data could be described assuming one of many
continuous distributions for p, 0 < p < 1. However, the most sensible distribution for p is the
beta distribution, because it is the natural conjugate prior distribution in the Bayesian sense.
It is well known that most SNPs present a very low minor allele frequency (MAF), close
to either 0 or 1 depending on the codification. However, these SNPs with very low MAF
are systematically excluded from GWAS. After elimination, it is often assumed that the allele
frequencies follow a uniform distribution. This is consistent with the beta approach, because
the uniform distribution in the interval [0,1] is the beta distribution with parameters α = β = 1.
However, the observed distribution of allelic frequencies is not quite uniform. Therefore, a finer
analysis of the observed distribution is required.
The beta distribution with parameters α and β is denoted by Beta(α, β) and has the following
probability density function (PDF)
f(a) =

Bα,β(a)∫
1
0
Bα,β(r)dr
, if 0 < a < 1;
0, otherwise.
where Bα,β(a) = a
α−1(1 − a)β−1 and 0 < α, β ≤ 1. The mean µ and variance σ2 of Beta(α, β)
are given by
µ =
α
α+ β
, σ2 =
αβ
(α+ β)2(α+ β + 1)
. (1)
Notice that the parameters α and β are determined by the mean and variance (1) by the following
formulae:
α =
µ(µ− µ2 − σ2)
σ2
, β =
(1− µ)(µ − µ2 − σ2)
σ2
. (2)
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In order to define variables, we assumed the allelic probability as the probability that one
of the possible alleles occurs. For this, we denoted the two most frequent alleles as A and B,
respectively. This symbolic association was performed at random with equal probability. The
allelic probability is defined as the probability of the occurrence of the allele denoted as A. This
introduces a random variable, referred as allelic probability (AP).
As explained above, since the values of AP are proportions, the random variable AP can be
modeled with a beta distribution Beta(α, β). As the chosen allele is determined at random the
mean of AP should be 0.5. In terms of the beta distribution this implies that α = β.
However, the beta distribution is not enough to properly model the allelic probability dis-
tribution in a real dataset. There are several considerations that we must take into account to
explain this situation. For example, the commercial genome-wide SNP chips designs or quality
controls (QC) applied to the genotyping studies, regularly exclude the SNPs with very small
MAF, those with Hardy Weinberg disequilibrium, and those with a poor quality, etc. Further-
more, the incorporation of imputation methods may also introduce bias in genome-wide allelic
distribution by imputing preferentially those SNPs with a higher MAF and those located in
regions in strong linkage disequilibrium. Thus, one cannot assume that AP takes all the values
in the interval [0, 1]. Either design-based or QC-based pruning of SNPs induce a truncation of
beta distribution.
Therefore, we may consider the random variable AP t of the truncated allelic probabilities in
a GWAS with the truncation t, following a beta distribution truncated in some interval [t, 1− t],
denoted as Beta(α,α, t, 1 − t). Its probability density function is given by:
g(a) =

Bα,α(a)∫
1−t
t
Bα,α(r)dr
, if t < a < 1− t;
0, otherwise.
(3)
Moreover, universal or general truncation exists in commercial chips that have been designed
based on data derived from worldwide populations as HapMap or 1000 genome project datasets.
In contrast, the DNA samples for a specific study are obtained from local populations. It is
well established that SNP frequencies vary geographically due to genetic drift and exceptionally,
due to natural selection in specific endemic regions. Therefore, a low MAF in studied local
population might not indicate necessarily an equivalent low MAF in worldwide populations. As
a consequence, selected SNPs in a commercial chip might not be observed in the local population,
yielding a very low MAF that displays allelic probability values close to 0 or 1. To further analyze
this phenomenon, we introduced the random variable a priori truncated local allelic probability,
LAPt, and the difference Dt = LAPt−APt, which measures the variation between the universal
allelic probability and the local allelic probability of a given SNP.
2.1.1 The local allelic probabilities
We assumed that Dt and APt are independent random variables. To guarantee local allelic
probabilities to be bound into the interval [0, 1] (see Appendix A), we assumed that Dt is
truncated in the interval [−t, t]. Hence we modeled Dt as a truncated normal distribution
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NT (0, δ,−t, t). Its probability density function is given by:
h(x) =

n0,δ(x)∫ t
−t n0,δ(r)dr
, if − t < x < t;
0, otherwise.
(4)
where n0,δ(x) =
1√
2π
e
x2
−2δ2 is the probability density function of a Normal distribution with mean
zero and standard deviation δ. Notice that the mean of Dt is equal to zero and its variance is
denoted by σ2D.
As APt and Dt were assumed to be independent. The probability density function of
LAPt = APt +Dt (5)
is the convolution of the probability density functions of APt and Dt.
As APt is distributed as Beta(α,α, t, 1 − t), it is straightforward that its mean should be
0.5. The variance of AP t was calculated using the incomplete beta function and the regularized
incomplete beta function as shown in Appendix B (19). On the other hand, as Dt follows a
NT (0, δ,−t, t) distribution, its mean value is zero and its variance is given by (6).
σ2D = δ
2
(
1− 2
t
δφ(
t
δ )
2Φ( tδ )− 1
)
, (6)
where φ and Φ are the PDF and CDF of the standard normal distribution N(0, 1) respectively.
Moreover, we have 0 ≤ σ2D ≤ t
2
3 (see Lemma B.1).
As AP t and Dt are independent, the variance of LAP = APt + Dt is σ2l = σ2u + σ2D and
hence
σ2u ≤ σ2l ≤ σ2u +
t2
3
.
This last expression includes the variance, taking into the account the noisy data. Indeed,
if a higher degree of noise exists, the Dt variance can be taken as its maximum value, σ2D = t
2
3 .
So, in this case, the expression σ2l ≈ σ2u + t
2
3 can be used as a good approximation for LAP
variance.
2.1.2 A real data example
In order to illustrate our approach we took the data from a practical case. The GWAS dataset
is an imputed GWAS with 1,237,567 SNPs and 1225 individuals genotyped by the Translational
Genomics Research Institute (TGEN) (Reiman et al. [2007]), previously processed as part of a
genome-wide meta-analysis looking for Alzheimer’s disease genetic risk factors (Antu´nez et al.
[2011, May 31]).
Figure 1 shows the comparison between the empirical allele frequencies with the PDF of
the uniform (A), beta (B) and truncated beta (C) distributions, where the empirical allele
frequencies are represented by dots and the PDFs are represented by continuous lines. The
parameters for the beta and truncated beta distribution were taken for the distribution to have
the same mean and variance as the empirical data. Figure 1 shows that the beta distribution
is not good enough to model the empirical allelic frequencies. The observed divergence mainly
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occurs in the two tails of the distribution where the theoretical beta distribution increases, while
the data dramatically decreases. The observed truncation is attributed to the removal of low
MAF alleles during QC and the relative inability of imputation methods to make good inferences
for low MAF SNPs.
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Figure 1: Empirical relative frequencies (dots) and uniform (A), beta (B), and truncated beta
(C) PDFs (continuous lines). (A) PDF of uniform distribution in [0, 1]. (B) PDF of Beta (α, β).
(C) PDF of Beta (α, β, t, 1 − t) . The parameters α, β of the beta distributions are taken to
fit the mean and variance of empirical relative frequencies (α = β = 0.928) and the truncation
is computed as the percentile 1 (t = 0.0218). The empirical frequencies have been calculated
grouping the data in 1000 intervals.
In order to fit the data to equation (5), we took t as the percentile 1 of the allelic probabilities:
t = 0.0218. Since σ2D belongs to the interval [0,
t2
3 ] so that we can estimate σ
2
D as if it is a uniform
random variable in such an interval. This means that the expected value of σ2D is calculated as
σ2D =
t2
6 = 7.9 · 10−5. Then, the parameter δ can be estimated as δ = 9.59 · 10−3 from (6).
Since t is known, σl can be estimated from the sample. As σu only depends on the parameters
α and t, the value of α can be computed by solving (see Appendix B),
σ2u = σ
2
α,t =
1
(4α+ 2)B(α,α)
tα(1− t)α(4t− 2)
1− 2It(α,α) +
α+ 1
4α+ 2
− 1
4
= σ2l −
t2
6
, (7)
where σ2α,t is the variance of the truncated beta distribution. Therefore, α = 0.7199 is obtained
from this equation. The three parameters, t, δ, and α determine the LAPt distribution fitting
to the dataset. Figure 2 shows the empirical relative frequencies (dots) and the model of allelic
probabilities LAPt (continuous line) with the parameters computed above.
The LAPt model fits much better to a real dataset than the previous analyzed models.
This is especially true for the tails of the probability distribution functions. Besides, the mean
squared error (MSE) estimator decreases for the new model. As shown in Table I, the minimum
MSE is reached for the LAPt model with 70.16% decrease in the MSE when compared with the
uniform model.
Table I: The Mean Squared Error calculated in the four different distributions
described fitting the empirical allelic probability grouped in 1000 intervals.
TGEN AP Uniform Beta Betat LAPt
MSE 0.0429 0.0517 0.0315 0.0128
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2.2 Case-control probabilities
We assumed a GWAS, where a SNP was typed for N individuals, with N0 controls and N1 cases.
Ms denotes the number of individuals which present a certain genotype (s).
Next we attempted to test for the following null hypothesis,
H0 : the absence of association in genotype s. (8)
Notice that under this null, the probability of being case conditioned to having a given
genotype s, bs, is the same as the probability of being case, b. In order to test this null, the
following binomial distribution, Bin(Ms, bs), consisting of number of cases with genotype s
can be considered. Under the null, bs can be estimated as b̂s = b̂ = N1/N . On the other
hand, as we mentioned before that the most sensible distribution for bs is the beta distribution,
Beta (αMs , βMs). This is based on the fact that the beta distribution is the conjugate prior of
the binomial distribution (MacKay [2003]).
The mean of bs can be estimated by µ = bˆs =
N1
N and its variance σ
2 = bˆs(1−bˆs)Ms =
N0N1
N2Ms
.
Since the population under study is finite it is necessary to adjust the variance σ2 for the
population size with the finite population correction factor N−MsN−1 (Isserlis [1918]). This is
specially required when sample size Ms is not small in comparison with the population size N ,
so that Ms > 0.05N . Therefore, when Ms > 5%N , the variance σ
2 remains as
σ2 =
N0N1(N −Ms)
N2Ms(N − 1) .
Thus, under the null hypothesis, we can estimate αMs and βMs ,
αMs =
N1
N
(
Ms(N − 1)
N −Ms − 1
)
and βMs =
N0
N
(
Ms(N − 1)
N −Ms − 1
)
. (9)
0.2 0.4 0.6 0.8 1.0
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Figure 2: Empirical relative frequencies (dots) of allelic probabilities of the TGEN sample,
with 1, 237, 567 SNPs and PDF of truncated Beta(α,α, t) + NT (0, δ, t) (continuous line) with
1225 individuals, where 757 are cases and 468 controls. The empirical relative frequencies were
estimated grouping the data in 1000 intervals between [0, 1].
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Figure 3 compares the empirical relative frequencies of bs in TGEN dataset (dots) with
the PDF of Beta (αMs , βMs) (continuous line) i.e., the beta distribution of bs under the null
hypothesis, for several values of Ms.
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Figure 3: Empirical relative frequencies of bs (dots) for genotypes with different numbers of
individuals (20, 50, 100, 200, 500 and 800 of individuals) and PDF of Beta(αMs , βMs) (continuous
line).
Thus, we obtained a decision rule for H0 at a desired confidence interval (CI) as,
Accept H0 if qǫ/2 ≤ bs ≤ q1−ǫ/2
Reject H0 otherwise
(10)
where ǫ is the type I error, qǫ/2 and q1−ǫ/2 the extreme p-values, and both are tied by the beta
distribution as,
ǫ/2 = Pr(Beta(αMs , βMs) < qǫ/2) = Pr(Beta(αMs , βMs) > q1−ǫ/2). (11)
Let p denote the proportion of individuals of the general population which presents a given
phenotype, and let cs denote the same proportion calculated in the individuals of a sample with
a given genotype s. The ratio ϕs = cs/p is called the effect of the genotype s on the phenotype
in a given sample and represents the proportion in which an individual with genotype s has
more probability of presenting a phenotype than general population. However, controls are a
representation of the population, while cases are a sample of individuals with the phenotype.
Therefore, it is possible to use the GWAS to find and estimation for cs, (see Appendix C). Also,
ϕs and bs can be related as
ϕs =
N0
N1
bs
1− bs , bs =
ϕsN1
N0 + ϕsN1
. (12)
These last expressions allow constructing a decision rule that takes into account the effect
(ϕs) of the genotype s.
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The new decision rule is written in the same way as (10) but in this case,
ǫ/2 = Pr(Beta(ξ0, ξ1) < q
′
ǫ/2) = Pr(Beta(ξ0, ξ1) > q
′
1−ǫ/2), (13)
where,
ξ0 =
ϕsN1
N0 + ϕsN1
(
Ms(N − 1)
N −Ms − 1
)
and ξ1 =
N0
N0 + ϕsN1
(
Ms(N − 1)
N −Ms − 1
)
. (14)
The measured effect, applying the decision rule (10) (ϕs), takes only into account the data
contained in the sample. However, the effect (ϕs) that delimits the rejection region for a given
confidence level ǫ can be computed from decision rule (13). Here, we called this effect as the crit-
ical effect of genotype s, with a certain confidence level ǫ and it is denoted as Ψǫs (Appendix C).
2.2.1 Exploring BT in different genetic models
The test for GWAS explained above, hereafter, would be referred as the Beta Test (BT) that
considers each genotype characteristic independently. This approach provides some new possibil-
ities with respect to the conventional association test based on contingency tables and hereafter,
would be called as Conventional Test (CT). In univariate CT, one can consider five genotype
characteristics corresponding to the two alleles (A and B) and their three possible combinations
(AA, AB and BB), separately.
Many contingency tables can be constructed in the CT by considering two or three genotype
characteristics. Similarly, many models can be used for the BT, considering the different non-
empty subsets of the genotype characteristic. For example, there are eight possibilities for both
univariate CT and BT. However, most of the models are not meaningful for genetic purposes.
For example, the allelic feature against the homozygous genotype or the heterozygous presence
compared to the dominant model are two comparisons that do not provide useful information.
On the other hand, the odds-ratio is not well defined when more than two characteristics are
considered.
Therefore, in practice, only five models are used, namely allelic (A versus B), dominant
(AA ∪ AB versus BB), recessive (AA versus AB ∪ BB), heterozygous (AA ∪ BB versus AB)
and genotype (AA versus AB versus BB).
Next, we focused our attention in the allelic CT model and the alleles A and B of BT models
because of the fact that the allelic CT model is the most common model used in GWAS. The
relationships among the models can be seen in Appendix D. The remaining models are available
from the authors upon request.
2.3 Measuring (or relating) locus effect in BT models
Conventionally, odds-ratio is the effect measure estimated in a case-control GWAS. Let ORa be
the odds-ratio in allelic model between cases and controls. The magnitude of effect of the allelic
CT model (ORa) can also be related to the effect of the BT. In other words, the effect of a given
model can be expressed as a function of ORa.
In order to simulate a case-control population, it is necessary to fix an odds-ratio value, for
example, ORa, and another parameter like the MAF of a population of controls. Let x0 be the
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MAF in a population of controls, and x1 the MAF in a population of cases. If ORa is fixed, x1
can be written as
x1 =
ORa · x0
1− x0 · (1−ORa) . (15)
Next, using the Hardy-Weinberg equilibrium (for short, HWE), it is possible to simulate the
case-control population of SNPs.
The odds-ratio, as usually understood, shows the difference between the probability dis-
tribution for being case and the probability distribution for being control. The BT assumed
a different null hypothesis: in each genotype characteristic, the probability of being case is
contained in a confidence interval centered around the proportion between cases and total pop-
ulation N1/(N0 + N1). This proportion can be measured with the effect ϕs, and it is fixed for
each genotype characteristic. From the HWE and using (15), the ORa and ϕs (for s = A or B)
are related as follows:
ϕA =
ORa
(1− x0 · (1−ORa)) and ϕB =
1
(1− x0 · (1−ORa)) . (16)
Remarkably, if allelic frequencies in cases and controls are equal, there is no effect in any
model. In other words, x0 = x1 implies that ORa = 1 and ϕs = 1. Figure 4 shows the effects
(ϕs) for different models as a function of the allelic odds-ratio (ORa ∈ [0, 10]).
Figure 4: In the 3D graphic A, there are the effect of s = A (ϕA) respect of the ORa between
zero and 10. In the 3D graphic B, there are the effect of s = B (ϕB) respect of the ORa between
zero and 10, for different values of MAF .
3 Monte Carlo Simulation
A simulated dataset, consisting of N1 = 1000 cases and N0 = 1000 controls, was analyzed with
both conventional chi-square (CT) and the new association (BT) tests in allelic models. A total
of 105 SNPs, with different minor allele frequencies (0 ≤ MAF ≤ 0.5), were simulated under
the null hypothesis i.e., to have no effect on the trait (ORa = 1 or all the effects are equal
to 1). This analysis can reflect whether the new Beta Test (BT) conforms to the theoretical
beta distribution, and compares how the Conventional Test (CT) conforms to the Chi-square
distribution. For estimating the type I error for each test (size of the test), we counted the
number of test-statistics that had values above the critical values of the expected distribution.
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Table II: Type I Error (size) for each model of Beta and Conventional tests, re-
spectively, taking the MAF as a random value between [0, 0.5] and different critical
values of the expected distribution with corresponding confidence levels (0.05, 0.01
and 0.001).1
Expected
BT
Allele A Allele B DomA DomB Homoz s=AA s=AB s=BB
0.05 0.0489 0.0491 0.0493 0.0476 0.0491 0.0496 0.049 0.0494
0.01 0.00989 0.00989 0.00986 0.00926 0.0103 0.00996 0.0104 0.00982
0.001 0.000978 0.000957 0.00101 0.000739 0.000926 0.00107 0.000968 0.000989
Expected
CT
ALLELIC DOM REC HETEROZ GENO
0.05 0.0491 0.0494 0.0477 0.0492 0.0466
0.01 0.00989 0.00981 0.00926 0.0103 0.00937
0.001 0.000957 0.000978 0.000739 0.000916 0.000947
1 The models are composed in BT by Allele A, Allele B, Dominant of A (AA ∪AB), Dominant of B
(AB ∪BB), Homozygous (AA ∪BB)s = AA, s = AB and s = BB. While in CT, the models are allelic (A
versus B), dominant (AA ∪AB versus BB), recessive (AA versus AB ∪BB), heterozygous (AA ∪BB versus
AB) and genotype (AA versus AB versus BB).
In order to simulate the case-control populations under certain conditions, only two param-
eters (MAF and an odds-ratio or ϕs) need to be fixed, as explained before. Indeed, fixing MAF
in controls and the effect (odds-ratio or ϕs), the entire population is already defined.
The populations were simulated by generating at each SNP a random value for genotypic
probabilities of controls according to MAF value and HWE. Once controls’ MAF value and effect
were fixed, the MAF values for cases were straightforwardly obtained, and following HWE, the
genotype probabilities were computed, generating the cases population.
Using this method, both tests, CT and BT, yielded approximately the expected number of
false positives (see Table II), suggesting they all conform to the expected theoretical distribu-
tions.
To estimate the power of both CT and BT, we carried out an analysis of a simulated dataset
of 1000 cases and 1000 controls. Sets of 105 SNPs were simulated under different alternative
hypothesis (see Table III), with different effect sizes and minor allele frequencies (0.05, 0.2 and
0.4), with a fixed confidence level ǫ = 0.05. The effect of the genotype characteristics is related
with the odds-ratio of corresponding model. Note that some scenarios could not be estimated
due to HWE restrictions. Our results showed that both tests detected SNPs in association with
similar power, depending on the new effect measurement and presenting there the allelic models
comparison.
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Table III: Power of both tests BT and CT in simulated data, taking SNPs under
the alternative of association, with different minor allele frequencies (MAF) and
effect sizes at allelic models (ϕA and ϕB).
1
Allele A MAF = 0.05 ϕA ∈ [0, 20] MAF = 0.2 ϕA ∈ [0, 5] MAF = 0.4 ϕA ∈ [0, 2.5]
Fixed ϕA MODEL POWER (in %) ORa POWER (in %) ORa POWER (in %) ORa
0.5
BT A 98.8
0.49
100
0.44
100
0.38
CT ALLELIC 98.89 100 100
0.67
BT A 74.4
0.66
99.99
0.62
100
0.55
CT ALLELIC 75.65 99.99 100
0.8
BT A 31.79
0.79
91.12
0.76
99.96
0.71
CT ALLELIC 33.27 91.12 99.96
1.25
BT A 40.26
1.27
96.7
1.33
100
1.5
CT ALLELIC 40.21 96.7 100
1.5
BT A 90.82
1.54
100
1.71
100
2.25
CT ALLELIC 90.75 100 100
2
BT A 100
2.11
100
2.67
100
6
CT ALLELIC 100 100 100
Allele B MAF = 0.05 ϕB ∈ [0, 1.05] MAF = 0.2 ϕB ∈ [0, 1.25] MAF = 0.4 ϕB ∈ [0, 1.67]
Fixed ϕB MODEL POWER (in %) ORa POWER (in %) ORa POWER (in %) ORa
0.8
BT B 100
6
100
2.25
100
1.63
CT ALLELIC 100 100 100
0.9
BT B 100
3.22
100
1.56
96.97
1.28
CT ALLELIC 100 100 96.97
0.95
BT B 100
2.05
86.36
1.26
48.67
1.13
CT ALLELIC 100 86.36 48.7
1.05
BT B 100
0.048
90.96
0.76
49.51
0.88
CT ALLELIC 100 90.96 49.53
1.1
BT B NA
doesn’t exist
100
0.55
97.62
0.77
CT ALLELIC NA 100 97.63
1.2
BT B NA
doesn’t exist
100
0.17
100
0.58
CT ALLELIC NA 100 100
1 First table is for allele A model and the second table for allele B model. For each effect size ϕ and each minor
allele frequency MAF the odds ratio of the allelic model ORa is reported using (16), at a fixed confidence level
ǫ = 0.05.
4 Application to Real Data
In order to apply the BT approach to real data, a GWAS dataset with 1, 237, 567 SNPs (where
N0 = 468 controls and N1 = 757 cases) was used (Section 2.1.2).
Table IV describes the parameters of the allelic probability distribution for cases, controls,
and total population. As already shown in Figure 2, there are no allele frequencies lower than
0.01; however, there exists some noise close to the extreme values.
The calculated probability of being case with a genotype characteristic s is very sensitive
to parameter Ms. This is shown in Figure 3, where bs is plotted for different values of Ms.
This implies that results depend on the frequency of having the genotype s and the sample size.
While making inference on the correlation of a phenotype and a genotype, one should take into
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Table IV: Summary of the TGEN allelic probabilities sample for cases, controls,
and cases and controls.
TGEN impQC2:
1,237,567 SNPs, 1225 individuals, 757 cases and 468 controls.
Cases & Controls Cases Controls
Empirical mean µ̂ 0.500065 0.500063 0.500065
Empirical variance v̂ 0.0916691 0.0917528 0.0917662
Minimum v̂ 0.01 0.01 0.01
Truncation P1 0.018605 0.018092 0.018233
α̂ 0.666681 0.671064 0.669102
δ̂ 0.01871 0.01561 0.01623
Mean Squared Error 0.0128 0.0154 0.013
account the number of individuals with such a genotype in the GWAS.
Figure 5: Manhattan plot of the new GWAS proposed with both alleles model in BT.
Figure 5 shows the Manhattan plot applied to the BT in the Allele A model within the
sample described above (TGEN). Associated SNP on chromosome 19 is not displayed in the
figure because of the chosen scale. This SNP is related to the apolipoprotein E (APOE) with a
significant p-value= 1.33 · 10−42 on BT.
Note that the CT is a one-tailed test where the null hypothesis of no association is rejected
if p−value is lower than ǫ and the direction of the effect determines the risk or protective role
of the SNP. However the BT is a two-tailed test, where the null hypothesis of no association is
rejected if p-value is lower than ǫ/2 or bigger than 1 − ǫ/2. In this case, the risk or protective
role of the SNP was determined not only by the direction of the effect but also by the region of
rejection. In other words, p-value≤ ǫ/2 implies ϕs ≥ 1 and vice-versa. Therefore, the p-value
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information is enough to define the risk or protection association.
4.1 Measuring the concordance between CT and BT
The agreement between two sets of results could be measured by the Kappa index (K) of
agreement (Cohen [1960]). In this case, we used two categories: being in association or not,
with different levels of confidence. Kappa index is the estimator of agreement, compared in the
paired models. At perfect agreement, K equals to one, while agreement given by chance gives a
value of K close to zero.
Table V presents the allelic model comparison with their corresponding BT models (Allele
A and Allele B). Notice that BT null hypothesis rejecting region contains approximately the
expected number of significant SNPs than its corresponding confidence level. Nonetheless, there
are some SNPs that reach significance in BT, but not in CT.
Table V: The allelic paired models compared with the Kappa index of agreement,
calculated in column Kappa, and the number of SNPs in concordance where both
tests detect or not an association with the phenotype with a confidence level ǫ. 1
K1 ALLELE A
cl Kappa Pos Conc CT-BT+ CT+BT- Neg Conc
ALLELIC
ǫ = 0, 05 0.97 61861 1944 1651 1172111
ǫ = 0, 01 0.94 11792 914 576 1224285
ǫ = 0, 001 0.777 946 314 228 1236079
K2 ALLELE B
cl Kappa Pos Conc CT-BT+ CT+BT- Neg Conc
ALLELIC
ǫ = 0, 05 0.993 63164 456 348 1173599
ǫ = 0, 01 0.985 12263 266 105 1224933
ǫ = 0, 001 0.976 1163 46 11 1236347
1 Pos Conc is the positive concordance, where both BT and CT reject the null hypothesis of no association.
Similarly, Neg Conc is the negative concordance, where both BT and CT accept the null hypothesis. BT+CT−
(respectively BT−CT+) represents the number of SNPs in discordance on both tests, where BT refuse
(respectively, accept) an association and CT accept (respectively, reject) it.
When comparing CT with BT model, the Kappa index showed some differences in the
association tests. For instance, a remarkable concordance (K = 0.976, ǫ = 0.001) was observed
while comparing the CT Allelic model with the BT Allele-B model (K2, Table V).
A remarkable result from Table V summarized in Table VI, reveals that all the SNPs, detected
in association with the phenotype in CT test, were also detected in association with the BT test
in any allele models (A or B). However, several SNPs detected being associated with the BT
(in Allele A or B model) were not detected by the CT (see Table VI). For example, for a given
confidence level ǫ = 0.001, the 23% of positives, that are SNPs refusing H0, were detected by
BT allelic models since CT allelic model could not detect them.
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Table VI: Summary of the number of SNPs detected with association in CT Allelic
model and both BT allele models (A and B) and their differences, with a confidence
level ǫ.1
Either allele A or B
Pos Conc CT- BT+ CT+ BT-
ǫ = 0.05 63512 2273 0
ǫ = 0.01 12368 1137 0
ǫ = 0.001 1174 354 0
1 Pos Conc is the positive concordance, where both BT and CT reject the null hypothesis of no association.
BT+CT− (respectively BT−CT+) represents the number of SNPs in discordance on both tests, where BT
refuse (respectively, accept) an association and CT accept (respectively, reject) it.
The difference between BT results and the corresponding CT can be surprising at times.
Indeed, one would expect much more concordance among CT and BT estimates. In order to
understand the observed differences, a comparison of parameters space is advisable.
4.2 Comparisons with Principal Component Analyses
Principal Components Analysis (PCA) is a measurement that shows the relationship between
two sets of parameters. We performed here PCA for analyzing the relationship between the
parameters from CT (p-value of the χ2 distribution and the odds-ratio ORi corresponding to
the model) and from BT (p-value of the beta distribution, the effect ϕs and the critical effect Ψ
ǫ
s).
PCA finds which parameters explain the maximum variability and also sorts the components
(transformed variables) by their explained variance; the original variables have corresponding
weights in each components (Pearson [1901]).
In summary, PCA found which variables explain the maximum variability in the CT and
BT results, the percentage of explained variance and the intensity.
Different variability explanation between allelic CT model and both alleles BT models using
three principal components is shown in Figure 6 (a. and b.). These figures show the proportion
explained variance is contributed by each parameter in the principal components. The p-value
and ϕs of the BT, and the odds-ratio OR of the CT explain the same variance, which means
these three parameters have the same direction as PC1. As expected, the p-value of CT (called as
pCHI) explains the variance along the second principal component. However, the Critical effect
of the BT Ψǫs complements the third principal component, which means that some variability
cannot be explained without it. As a matter of fact, the Critical effect contributes to the 87.72%
of the third principal component, which explains the 15.17% of the total variance.
Therefore, the principal component analysis reflects that the results of both methods must
differ in a region of the explaining variance.
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4.3 Ranking of association
Top results for BT analysis are presented in Table VII. Briefly, we displayed the ranking of the
smallest p-values in BT (< 10−5) including either A or B allele estimation and their correspond-
ing results using conventional one degree of freedom chi-squared tests applied to MAF (CT).
We also included the ranking order observed for each marker using both approaches (BT and
CT). As expected, most SNPs, but not all of them, exhibited very similar p−values and ranking
order. This result is fully compatible with the performance of the global kappa index (Table V).
A whole and comprehensive ranking is also included (Supplementary file “RankingTGEN-
pvalueBT.csv”). Of course, both strategies identified SNP marker rs4420638 on chromosome 19,
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Figure 6: The weights of the parameters in each Principal Component (the first with the
second, the first with the third and the second with the third, respectively), taken for the
variables of the Allelic model of CT is compared to the Allele A and B models of BT. It
describes the eigenvalues (in %) of each principal component.
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Table VII: Top smallest p−values computed with the BT for the Alleles A and B
models (< 10−5) in the TGEN dataset, described above (* symbol represents that
several markers in LD have been omited in a single signal with the lowest p−value).1
CHR BP SNP MAF A1 A2 pvBT BT-Allele ϕA ϕB Psi
0.05
A Psi
0.05
B pvCT ORa MA MB
19 50114786 rs4420638 0,308 G A 1,33E-42 1 2,44 0,72 2,12 0,76 2,21E-34 3,39598 754 1694
3 52481466* rs6784615 0,069 C T 9,43E-08 1 2,30 0,95 1,64 0,97 2,09E-06 2,43106 170 2278
5 121942614 rs11953981 0,058 G A 9,60E-07 1 2,45 0,95 1,70 1,03 1,83E-05 2,56819 128 2086
12 93847903 rs249152* 0,193 A G 2,64E-06 1 1,49 0,91 1,26 0,96 1,16E-05 1,63099 464 1938
2 51804001 rs17864593* 0,016 A G 3,02E-06 1 5,40 0,98 2,24 1,00 NA 5,51085 39 2329
2 205265992 rs41511746 0,017 G C 3,76E-06 2 0,25 1,02 0,47 1,01 7,82E-06 0,241278 42 2408
16 26556972 rs12162084 0,157 A G 4,10E-06 2 0,66 1,08 0,80 1,04 9,34E-06 0,611134 385 2063
1 21773864 rs1536934 0,069 A G 4,21E-06 2 0,51 1,05 0,69 1,02 9,17E-06 0,479325 153 2057
10 68271216 rs4486514 0,04 C T 4,30E-06 1 2,71 0,97 1,69 1,01 7,54E-05 2,80962 93 2231
10 112534645 rs7077757* 0,211 T C 5,22E-06 2 0,71 1,10 0,83 1,05 1,21E-05 0,645986 515 1925
15 90462008 rs11074041* 0,142 C G 5,45E-06 2 0,64 1,08 0,78 1,03 1,23E-05 0,597382 335 2019
18 71895842 rs359739* 0,192 A C 6,64E-06 1 1,46 0,92 1,22 0,95 2,58E-05 1,59007 470 1976
8 47534249 rs4313171 0,067 T C 7,68E-06 2 0,53 1,05 0,71 1,03 1,65E-05 0,502977 165 2285
22 17002691 rs12168275 0,038 G C 8,38E-06 1 2,72 0,97 1,65 1,00 0,00013 2,80573 87 2215
5 117744488 rs6595122 0,282 C A 8,61E-06 2 0,75 1,12 0,86 1,06 2,06E-05 0,667943 637 1621
19 50323656 rs17643262* 0,082 A G 9,07E-06 1 1,88 0,95 1,37 0,97 5,69E-05 1,97991 192 2148
9 5583190 rs10815248 0,042 A T 9,23E-06 1 2,49 0,97 1,58 0,99 0,00011 2,57753 101 2309
10 53698470 rs10824310 0,065 T C 9,42E-06 2 0,52 1,05 0,71 1,03 2,02E-05 0,500702 159 2291
16 77974064 rs7192960 0,129 T C 9,57E-06 2 0,64 1,07 0,79 1,04 2,12E-05 0,59958 316 2134
1 The columns represent from left to right the number of chromosome (Chr), the base pair position of the SNP
(BP), the name of the SNP (SNP), the MAF value, code for minor allele (A1), code for the other allele (A2),
the lowest p−value of BT allelic models (pvBT), the number of the allele model with lowest p−value of BT
allelic models (BT-Allele), the effect of BT allelic models (ϕA and ϕB), the Critical effect of BT allelic models
(Psi0.05A and Psi
0.05
B ), the p−value of the CT (pvCT), the odds-ratio of this model (ORa) and the number of
individuals which present this alleles (MA and MB).
located 14 kilobase pairs distal to the APOE epsilon variant as the major finding. This obser-
vation was previously reported by TGEN researchers (Coon et al. [2007, Apr]). APOE locus is
the most important genetic risk factor for Alzheimer’s disease reported to date (Corder et al.
[1993, Aug]). Notably, we found APOE locus significance more than eight orders of magnitude
smaller using BT compared to CT (Table VII).
The rest of top markers also display smaller p-values using BT compared to CT calculations.
This can be explained by the fact that the CT is a one-tailed test where the null hypothesis of
no association is rejected if p-value turns out to be less than ǫ, while the BT is a two-tailed test
(where the risk or protective role of the SNP is known by the p-value) and the rejection area for
BT is one half that for CT (ǫ/2).
Notice that the non-available p-value for the CT in the Chromosome 2 is due to the lack of
data in a given cell. Anyway, this can be corrected by the Fisher test, which is not generally
recommended due its computational cost.
5 Discussion
Any description of allelic distributions in the genome must begin by constructing a model of
allelic probabilities. However, this important point remains unaddressed in many scientific
literature, at least to the best of our knowledge. Indeed, almost all simulations, made for testing
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a GWAS method, assume that allelic frequencies follow a uniform distribution. Here a model
for allelic probability distribution is proposed and tested. In addition, we also improved the
commonly used uniform distribution model.
The proposed alleles probability model, LAPt, offers a common scenario for each data set,
characterizing noise. The truncation when not known can be estimated using the empirical
distribution of the allelic probabilities. Regardless of the truncation, the remaining noise (quality
control, stratification, insufficient population, etc...) is gathered with the variable Dt.
The model depends only on the population of cases, controls, and the number of occurrences
of the feature in the sample. Although the study was focused in a univariate analysis and s
can be taken as the genotype in a single SNP, note that s is, in general, a vector and can
represent any desired condition. For instance, s can include, along the genotype, the sex, age or
other information. Furthermore, this vector can also include more than one genotype whether
considering their interactions (epistasis) or not.
Although the examples used in this work described the allelic model, any other models could
also be also analyzed without further modification of the method.
The new genome-wide association method (BT) has some commonalities with the conven-
tional one. However, BT offers a remarkable ranking variability that might represent genuine
signals. Novel candidate must be corroborated by intensive replication, multiple testing control,
and meta-analysis using other datasets. We are aware that if BT can isolate novel loci, which
generally missed while using traditional approaches, its application may help to uncover a frac-
tion of the missing piece of heritability still pending for multiple complex traits. Consequently,
next step of our research would be the generation of well powered meta-analysis of BT rankings.
The isolation of genome-wide significant signals, and ultimately, the replication in independent
series may help to measure the utility of this novel GWAS approach.
A Allelic probabilities variations
The difference between truncated universal allelic probability, APt, and a priori truncated lo-
cal allelic probability, LAPt, can be described in a single expression, Dt = APt − LAPt the
divergence of local MAF from commercial chips truncation for small MAF. Since the expected
values of APt and LAPt should be equal, we assumed that the expected value of Dt as zero,
and its seemed a plausible assumption that Dt follows a normal distribution. However, this
would give rise to local allelic probabilities out of the interval [0, 1]. To avoid this, we assumed
that the values of APt in the SNPs present in the chip belong to the interval [t, 1− t], and the
observed allelic probability takes values in [0, 1]. Therefore, the observed values of Dt belong to
the interval [0, 1]. Hence, we modeled Dt as a truncated normal distribution NT (0, δ,−t, t). Its
probability density function is given by
h(x) =

1√
2pi
e
x2
−2δ2
∫ t
−t
1√
2pi
e
x2
−2δ2
, if − t < x < t;
0, otherwise,
(17)
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The mean of Dt is 0 and its variance is given by
σ2(Dt) = σ2D = δ2
(
1− 2
t
δ (
t
δ )
2Φ
(
t
δ
)− 1
)
where φ and Φ are the PDF and CDF of the standard normal distribution N(0, 1), respectively.
If we take x = tδ then
σ2D = t
2
1− 2xφ(x)2Φ(x)−1
x2
 = t2( 1
x2
− 2φ(x)
x(2Φ(x)− 1)
)
.
As APt and Dt were assumed to be independent the density function of
LAPt = APt +Dt
is the convolution of the probability density functions of APt and Dt:
(g ∗ h)(z) =
∫ +∞
−∞
g(z − x)h(x)dx (18)
B Properties of truncated allelic distribution
As APt is distributed as Beta(α,α, t, 1− t), the mean of AP t should be µα,t = 0.5. This can be
easily deduced from its PDF g(a) (see (3)).
In order to calculate the variance of APt, it is convenient to use the incomplete beta function,
which is defined as
B(t;α, β) =
∫ t
0
aα−1(1− a)β−1da.
This function is related with the beta function Beta(α, β) using the regularized incomplete beta
function:
It(α, β) =
B(t;α, β)
B(α, β)
They satisfy the following properties (Paris [2010])
B(α + 1, β) =
α
α+ β
B(α, β)
It(α, β) = 1− I1−t(β, α) (19)
It(α+ 1, β) = It(α, β) − t
α(1− t)β
αB(α, β)
By (1), the variance σ2α of Beta(α,α) is
1
4(2α+1) . Using (19) we calculated the variance of
the truncated beta distribution:
σ2α,t =
∫ 1−t
t
aα+1(1− a)α−1∫ 1−t
t r
α−1(1− r)α−1
dr − µ2α,t
=
B(α + 2, α)(I1−t(α+ 2, α)− It(α+ 2, α))
B(α,α)(I1−t(α,α) − It(α,α)) −
1
4
=
α+ 1
4α + 2
tα(1−t)α(4t−2)
(α+1)B(α,α) + 1− 2It(α,α)
1− 2It(α,α) −
1
4
=
1
(4α + 2)B(α,α)
tα(1− t)α(4t− 2)
1− 2It(α,α) +
α+ 1
4α + 2
− 1
4
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Therefore, the variance of AP t is
σ2u = σ
2
α,t =
1
(4α + 2)B(α,α)
tα(1− t)α(4t− 2)
1− 2It(α,α) +
α+ 1
4α+ 2
− 1
4
. (20)
Next, we needed the following technical lemma.
Lemma B.1. Let f(x) = 1
x2
− 2φ(x)x(2Φ(x)−1) . Then f(x) is decreasing for x > 0, f(x) < 13 for
every x > 0 and limx→0 f(x) = 13 .
Proof. First, we need to prove that f(x) < 0, if x > 0. For that, we consider the function
g(x) = 2Φ(x)− 1 + 6xφ(x)
x2−3 . Having in mind that φ
′(x) = −xφ(x) and Φ′(x) = φ(x), we have
g′(x) = 2φ(x)
(
1 + 3
(1− x2)(x2 − 3)− 2x2
(x2 − 3)2
)
= − 4x
4φ(x)
(x2 − 3)2 ≤ 0.
Thus, g is strictly decreasing function in each region where it is continuous, for example, the
interval (0,
√
3). Let 0 < x <
√
3. As g(0) = 0, we deduce that g(x) < 0. As x2 − 3 < 0, we
have 0 < (x2 − 3)g(x) = (2Φ(x) − 1)(x2 − 3) + 6xφ(x). Pleanly (2Φ(x) − 1)(x2 − 3) + 6xφ(x)
is also positive if x ≥ √3. This proves that (2Φ(x) − 1)(x2 − 3) + 6xφ(x) > 0 for every x > 0.
Using that 2Φ(x)− 1, x2 > 0, we deduce that 3−x2
3x2
− 2φ(x)x(2Φ(x)−1) < 0 and hence
f(x) =
1
x2
− 2φ(x)
x(2Φ(x) − 1) =
1
3
+
3− x2
3x2
− 2φ(x)
x(2Φ(x)− 1) <
1
3
,
as desired.
Using L’Hoˆpital rule, we have limx→0
2Φ(x)−1
xφ(x) = limx→0
2
1−x2 = 2. Applying L’Hoˆpital again,
we have
lim
x→0
(
1
x2
− 2φ(x)
x(2Φ(x)− 1)
)
= lim
x→0
2Φ(x)− 1− 2xφ(x)
x2(2Φ(x)− 1)
= lim
x→0
xφ(x)
2Φ(x)− 1 + xφ(x) = limx→0
1
2Φ(x)−1
xφ(x) + 1
=
1
3
To prove that f(x) is decreasing for x > 0, we consider the following functions
ψ(x) = 2Φ(x)− 1
α(x) = (x4 − 2x2 + 3)
√
x4 + 2x2 + 9 + x6 − x4 + 5x2 − 9.
h(x) = 2ψ(x) − xφ(x)(x2 + 1 +
√
x4 + 2x2 + 9).
We claim that α(x) > 0 for every x > 0. For that we use the following equality
(x4 − 2x2 + 3)2(x4 + 2x2 + 9)− (x6 − x4 + 5x2 − 9)2 = 32x4. (21)
Therefore
(x4 − 2x2 + 3)2(x4 + 2x2 + 9) > (x6 − x4 + 5x2 − 9)2.
Moreover, x4 − 2x2 + 3 = (x2 − 1)2 + 2 > 0 and, if 0 < x < 1 then x6 − x4 + 5x2 − 9 < 0. Thus,
if 0 < x < 1 then (x4 − 2x2 + 3)√x4 + 2x2 + 9 > −x6 + x4 − 5x2 + 9, or equivalently α(x) > 0.
This equality also holds for x > 1 because both x4− 2x2+3, x4+2x2+9 and x6− x4+5x2− 9
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are increasing for x > 1. Therefore if x > 1 then α(x) ≥ α(1) = 2√12 − 4 > 0. This proves the
claim.
Let x > 0. As
h′(x) = φ(x)
(
4 + x2(x2 + 1 +
√
x4 + 2x2 + 9)−
(
3x2 + 1 +
√
x4 + 2x2 + 9 +
x(4x3 + 4x)
2
√
x4 + 2x2 + 9
))
=
φ(x)√
x4 + 2x2 + 9
(
(x4 − 2x2 + 3)
√
x4 + 2x2 + 9 + (x2 − 1)(x4 + 2x2 + 9)− 2x2(x2 + 1)
)
=
φ(x)√
x4 + 2x2 + 9
(
(x4 − 2x2 + 3)
√
x4 + 2x2 + 9 + x6 − x4 + 5x2 − 9
)
=
φ(x)α(x)√
x4 + 2x2 + 9
we conclude that h is an increasing function, therefore, h(x) > h(0) = 0. Equivalently
ψ(x) >
xφ(x)(x2 + 1 +
√
x4 + 2x2 + 9
2
. (22)
As the greatest root of the quadratic polynomial q(T ) = T 2 − (x3 + x)φ(x)T − 2x2φ(x)2 is
xφ(x)(x2+1+
√
x4+2x2+9)
2 , inequality (22) implies that q(ψ(x)) > 0. Hence
f ′(x) = − 2
x3
− 2−x
2φ(x)ψ(x) − φ(x)ψ(x) − 2xφ(x)2
x2ψ(x)2
= −2q(ψ(x))
x3ψ(x)2
< 0.
Thus f is decreasing for x > 0, as desired.
By Lemma B.1 we have 0 ≤ σ2D ≤ t
2
3 .
As APt and Dt are independent, the variance of LAPt = APt +Dt is σ2l = σ2u + σ2D, hence,
σ2u ≤ σ2l ≤ σ2u +
t2
3
.
Notice that the case σ2l = σ
2
u +
t2
3 occurs for the highest degree of noise, i.e., when Dt has
maximum variance σ2D =
t2
3 .
C The effects of a genotype s: ϕs, Ψ
ǫ
s
We defined the discrete random variable F , which takes only two values 0 and 1 depending on
whether the individual is a control or a case, respectively. Let M0s and M1s be the number of
controls and cases with the given genotype s, respectively, and let Ms = M0s +M1s. Let bs
denote the theoretical probability of being a case for an individual with genotype s in a GWAS
with N0 controls and N1 cases.
We assumed that the presence of the genotype multiply by a factor ϕs as the probability of
presenting a phenotype. We denoted the probability of having the phenotype for the individuals
with genotype s in the general population as cs. Let p be the expected value of cs, which is
usually called the prevalence of the phenotype in the general population. Therefore,
pϕs = cs = P (F = 1|s) = P (F = 1, s)
P (s)
=
P (F = 1)P (s|F = 1)
P (s)
=
pP (s|F = 1)
P (s)
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Since controls are a representation of the population and cases are a sample of individuals with
the phenotype, then we can compute the following estimations:
bs ≈ M1s
Ms
, P (s) ≈ M0s
N0
and P (s|F = 1) ≈ M1s
N1
Therefore
ϕs ≈ N0
N1
M1,s
M0,s
=
N0
N1
M1,s/Ms
1−M1,s/Ms =
N0
N1
b̂s
1− b̂s
and so
b̂s =
csN1
pN0 + csN1
=
1
pN0
csN1
+ 1
=
ϕsN1
N0 + ϕsN1
.
Next, we proceeded as in the tests statistics defined in (10) for the new bs that takes into
account the effect of the genotype s. Therefore, we may construct similar statistics in the same
way as above, where the decision rule at a 100(1 − ǫ/2)% are
Accept H ′0 if ω
′
ǫ/2,ϕ ≤ b̂s ≤ ω′1−ǫ/2,ϕ
Reject H ′0 otherwise
(23)
where Pr(Beta(α′Ms , β
′
Ms
) < ω′ǫ/2,ϕ) = Pr(Beta(α
′
Ms
, β′Ms) > ω
′
1−ǫ/2,ϕ) = ǫ/2, and
α′Ms =
ϕN1
N0 + ϕN1
(
Ms(N0 + ϕN1 − 1)
N0 + ϕN1 −Ms − 1
)
and β′Ms =
N0
N0 + ϕN1
(
Ms(N0 + ϕN1 − 1)
N0 + ϕN1 −Ms − 1
)
.
Here, we defined a new parameter, called the critical effect of the genotype s, with a certain
confidence level ǫ as the effect value, ϕs, of the expected distribution under the decision rule
(13) where bs = q
′
1−ǫ/2 if bs > bˆ =
N1
N or bs = q
′
ǫ/2 if bs ≤ bˆ = N1N .
That is, the critical effect size Ψǫs of genotype s at a ǫ confidence level is the greatest real
number ϕs (respectively lowest), such that the test given by (10) for bs =
ϕsN1
N0+ϕN1
rejects the
null hypothesis.
D Relationships among the models
Figure 7 shows how the models of CT and BT could be connected. Each considered variable
(AA, BB or AB) was treated as a different model. This implies that there is no one-to-one
correspondence between CT and BT models. For instance, the allelic CT model is not equal to
the probability of being case with the allele A or B, as analyzed in BT model. On the contrary,
both cases (A and B) must be taken into account when compared to the allelic CT model.
Thus, there are eight models in the BT which seems to be of interest: allele A (A), allele B
(B), dominant of A (AA∪AB), recessive of A (AA), dominant of B (AB ∪BB), recessive of B
(BB), homozygous (AA ∪BB) and heterozygous (AB). Thus, summarizing that there are five
interesting models for CT against eight meaningful models for the new BT.
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Figure 7: Paired models, i.e. relationships between the models of Conventional Test (CT),
composed by allelic, heterozygous, recessive, and dominant; the new test proposed, called the
Beta Test (BT), composed by allele A (BT a = A), allele B (BT a = B), s = AA (BT s = 0),
s = AB (BT s = 1), s = BB (BT s = 2), dominant of A (BT s =DomA), dominant of B (BT
s =DomB), and homozygous (BT s =Hom).
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